After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 484.89% and ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...

Tirzepatide is the active ingredient in the FDA-approved versions of the drug, Mounjaro and Zepbound, which are made by the ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

Eli Lilly (LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that ...

Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep ...